文献速递生殖医学

患者对IVF附加项目有效性与可接受性的焦点小组定性研究

Attitude and acceptability of IVF add-ons to improve reproductive outcomes: a focus group qualitative study.
PubMed 文献 · Hum Reprod · 2026-10-29

该研究通过三个在线焦点小组,访谈12名曾使用辅助生殖技术且当前未在治疗的英国女性,探讨患者评估IVF附加项目疗效、安全性、费用和可接受性时的关键因素。结果显示,活产是最重要结局,但中间里程碑也被重视;疗效比费用和安全性更受重视,费用与后悔风险仍是决策考量。

要点

  • 患者认为IVF附加项目最重要结局是活产,但中间里程碑可作为成功指标。
  • 患者需在风险与生育渴望之间权衡,费用需与未来治疗资金需求平衡。
  • 附加项目疗效比费用和安全性更受重视,费用与后悔风险仍影响决策。

核心结论

  • 疗效是患者评估IVF附加项目的最重要因素,但中间成功指标也重要。
  • 多数参与者不会后悔使用附加项目,部分人可能后悔未使用。

研究设计与样本

  • 三个在线焦点小组,共12名曾使用辅助生殖技术且当前未在治疗的英国女性。
  • 焦点小组每组3至5人,每次约2小时,参与者通过生育慈善机构和患者倡导组织招募。

主要发现

  • 几乎所有参与者将活产定义为使用附加项目的最重要结局。
  • 患者认识到活产在IVF治疗中可能感觉遥远,因此重视中间里程碑作为成功指标。
  • 理解风险的主要主题是患者需在风险与生育渴望之间平衡。
  • 费用方面出现两个主题:需平衡费用与未来治疗资金需求,以及对可接受费用存在不同观点。
  • 获取附加项目信息时,参与者重视寻找可靠来源并需应对冲突信息。

临床怎么用

  • 临床沟通应兼顾活产结局与中间里程碑,帮助患者理解附加项目疗效证据。
  • 讨论附加项目时需关注患者对风险与生育渴望的权衡及费用顾虑。
  • 提供附加项目信息时应引导患者识别可靠来源并处理冲突信息。

局限性

  • 所有参与者均为女性,且多数为白人, findings可能不适用于其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What factors are important for patients when evaluating the efficacy, safety, cost, and acceptability of IVF add-ons? SUMMARY ANSWER: Although efficacy is the most important factor for patients, interim markers of success can also be important. WHAT IS KNOWN ALREADY: IVF add-ons are increasingly offered alongside assisted conception despite limited evidence of their efficacy, safety, or value for money. Capturing patient perspectives on their acceptability and outcome priorities is essential to guide ethical clinical practice and inform future research. STUDY DESIGN, SIZE, DURATION: Three online focus groups were conducted with 12 people who had used assisted reproductive technologies and were not currently in treatment. The focus groups were conducted in small groups of three to five people with each focus group lasting ∼2 h. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants were recruited through fertility charities and patient advocacy groups. All 12 participants were women and lived in the UK. All were currently in a relationship, and most had prior experience of using IVF add-ons. Online focus groups were conducted to discuss views on the efficacy, safety, and acceptability of IVF add-ons, and to identify preferred outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: Nearly all participants defined the most important outcome of using an add-on to be achieving a live birth. However, they recognized that a live birth could feel a distant endpoint within the IVF treatment and therefore valued interim milestones as indicators of success. The main theme found in relation to understanding the risks involved was the need for patients to balance risk with desperation to have a baby. In terms of cost, two themes emerged, the need to balance cost with needing money for future treatments and the differing views on what is an acceptable cost. When receiving information about add-ons, participants reflected on the importance of finding reputable sources while also having to navigate conflicting information. Overall, the effectiveness of an add-on was valued over cost and safety, although cost and the risk of regret remained important considerations in decision-making. Most participants would not regret using add-ons, although some said they may regret not having used them. LIMITATIONS, REASONS FOR CAUTION: All participants were women, and most were White. Findings may not be applicable to other populations. WIDER IMPLICATIONS OF THE FINDINGS: Capturing participants' views on efficacy, safety, cost, and acceptability is essential not only to guide future research priorities but also to inform ethical clinical practice and policy. By incorporating patient perspectives, future trials can ensure that outcomes reflect what matters most to those undergoing treatment, thereby improving the relevance and impact of research in reproductive medicine. FUNDING: AFFINITY is funded by a public research grant from the National Institute for Health and Care Research's (NIHR) Efficacy and Mechanism Evaluation (EME) programme-Award ID NIHR168789. DISCLOSURES: The authors have no conflict of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Khan K, Nicholson L, Osinibi M, et al. Attitude and acceptability of IVF add-ons to improve reproductive outcomes: a focus group qualitative study. Hum Reprod. 2026. PMID: 42951382. doi:10.1093/humrep/deag164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。